SPEER-4D Inhibitors
SPEER-4D inhibitors pertain to a specialized class of chemical compounds characterized by their specific mechanism of action, which involves the selective targeting and modulation of particular molecular pathways within cells. The acronym SPEER stands for Selective Plasticity Enhancers of Endocannabinoid Reuptake, with the 4D signifying a fourth-generation advancement in this class of compounds. These inhibitors are designed to interact with the endocannabinoid system, a complex network of receptors, enzymes, and endogenous ligands that play a crucial role in regulating a multitude of physiological processes. By focusing on the reuptake aspect of this system, SPEER-4D inhibitors are able to influence the levels of endocannabinoids available in the synaptic space, thereby modulating the signaling events that occur between cells.
The structural design of SPEER-4D inhibitors is a product of extensive medicinal chemistry efforts aimed at achieving high specificity and selectivity. These molecules are often characterized by their ability to bind with high affinity to the transport proteins responsible for the reuptake of endocannabinoids, such as anandamide and 2-arachidonoylglycerol. The particular configuration and the functional groups present in these inhibitors are crafted to ensure that they effectively alter the normal reuptake process, leading to an increase in the concentration of endocannabinoids in the extracellular environment. Their selectivity is crucial in order to minimize off-target effects and to maintain the delicate balance within the endocannabinoid system. The 4D aspect may also imply additional dimensions of drug development, such as improved pharmacokinetic properties or enhanced bioavailability, which are achieved through the incorporation of advanced chemical modifications that differentiate these inhibitors from earlier generations of related compounds.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $36.00 $149.00 | 11 | |
As an antimetabolite, 5-Fluorouracil inhibits thymidylate synthase, leading to a decrease in DNA synthesis. This reduction in DNA synthesis can lead to decreased expression of SPEER-4D if its expression is tightly linked to cell proliferation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin binds to FKBP12 and the complex inhibits mTOR, a key regulator of protein synthesis and cell growth. Inhibition of mTOR could lead to reduced protein synthesis, potentially affecting the levels of SPEER-4D. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor. By altering chromatin structure and gene expression, it can indirectly lead to the downregulation of specific proteins including SPEER-4D if its expression is controlled by acetylation states. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor, which prevents the activation of AKT, leading to inhibition of downstream signaling involved in cell survival and growth. Reduced AKT activity could potentially lower SPEER-4D levels if they are linked to these pathways. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
SB431542 selectively inhibits ALK5, which is involved in TGF-beta signaling. By disrupting this pathway, cellular processes that could affect the expression or activity of SPEER-4D might be impacted if SPEER-4D is involved in TGF-beta signaling. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an MEK inhibitor that disrupts the MAPK/ERK signaling pathway. This pathway modulates various cellular activities, and inhibition could lead to reduced expression of SPEER-4D if it is regulated by ERK signaling. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $40.00 $82.00 $256.00 | 127 | |
Cycloheximide inhibits protein biosynthesis by interfering with the translocation step in protein synthesis. This could lead to a general decrease in protein levels, including SPEER-4D, especially if it has a short half-life. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor that can lead to the accumulation of misfolded proteins and disrupt various cellular signaling pathways. This could indirectly decrease SPEER-4D levels by affecting its degradation or the signaling pathways that regulate its expression. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 selectively inhibits MEK, which is involved in the MAPK/ERK pathway. This inhibition could lead to altered expression or activity of SPEER-4D if it is implicated in this signaling cascade. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a PI3K inhibitor that prevents the phosphorylation and activation of AKT. Inhibition of this pathway could decrease SPEER-4D levels if SPEER-4D is dependent on PI3K/AKT signaling for stability or expression. | ||||||